Sayan Mullick Chowdhury's research while affiliated with The Ohio State University and other places

Publications (14)

Article
Full-text available
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study a...
Article
Most patients receiving CAR T-cell therapy (CAR-T) for aggressive B-cell lymphoma (B-NHL) will not experience a durable remission. There are several novel agents approved for the treatment relapsed, refractory aggressive B-NHL; however, it remains unclear how to sequence these therapies pre- and post-CAR-T (peri-CAR-T). We conducted a multicenter r...
Article
Full-text available
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous non-Hodgkin lymphoma. No consensus exists regarding the standard-of-care in patients with advanced-stage disease. Current recommendations are largely adapted from follicular lymphoma for which bendamustine with rituximab (BR) is an established approach. We analyzed the safety and efficacy...
Article
Introduction: A common initial treatment approach for PTLD includes reduction of immunosuppression (RIS) and single-agent rituximab, followed by sequential chemoimmunotherapy for non-responding patients (pts). However, in relapsed disease, there is less consensus on optimum therapy. Moreover, there are very limited data regarding the use of chimeri...
Article
Background: Anti-CD19 chimeric antigen receptor T-cell therapy (CART) is a highly active therapy for relapsed/refractory (R/R) aggressive B-cell lymphoma. Nonetheless, most patients (pts) ultimately develop progressive disease (PD). There is little guidance on the optimal treatment approach(es) for these pts. We performed a multicenter retrospectiv...
Article
Introduction The treatment of aggressive B-cell NHL has evolved rapidly over the last 5 years, owing to the FDA approval of 3 CD19 CAR T-cell constructs (CARTs) along with other novel targeted therapies. Real world practice data suggest that CARTs have been successfully administered in populations typically excluded from clinical trials. However, d...
Article
Background Primary bone diffuse large B cell lymphoma (DLBCL) is a variant of extranodal non-Hodgkin lymphoma (NHL) that is relatively rare, accounting for 3-15% of extranodal NHL and less than 1% of all NHL. Patients often present with pain and swelling or pathologic fracture of the affected area of the skeleton, and B symptoms are often less prev...
Article
Introduction Ibrutinib was FDA approved for relapsed or refractory (R/R) marginal zone lymphoma (MZL) based on a phase II clinical trial that showed an overall response rate of 48% (Noy et al, Blood 2017). However, factors associated with response to ibrutinib in R/R MZL and outcomes of patients after progression on ibrutinib are unknown. Given the...
Conference Paper
Introduction: There is no standard induction therapy in extranodal marginal zone lymphoma (EMZL); current guidelines borrow from follicular lymphoma, where bendamustine and rituximab (BR) is an accepted standard. The data on BR in EMZL is limited (Rummel MJ et al. Lancet 2013 & Salar A et al. Blood 2017), so we explored BR activity as part of an in...
Article
Background: Current standard of care for most patients (pts) with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) is systemic salvage chemotherapy followed by autologous stem cell transplant (ASCT). Given the treatment-related toxicities associated with ASCT and the expanding novel therapeutic options, it is desirable to identify pts with...
Article
Key Points • Ibrutinib-resistant ABC-DLBCL cells exhibit compensatory upregu-lated PI3K/AKT axis that contribute to enhanced survival. • Combining dual selective inhibitor PI3K-b/d with other chemothera-peutic agents may sen-sitize ibrutinib-resistant DLBCL cells to chemotherapy. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of n...
Article
Full-text available
Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B–Cell lymphomas. Although the BTK-targeting agent ibrutinib has shown promising clinical responses, the presence of primary or acquired resistance is common and often leads...
Article
Full-text available
Lymphoma, a group of widely prevalent hematological malignancies of lymphocyte origin, has become the focus of significant clinical research due to their high propensity for refractory/relapsed (R/R) disease, leading to poor prognostic outcomes. The complex molecular circuitry in lymphomas, especially in the aggressive phenotypes, has made it diffi...

Citations

... Although predictive value of PET/CT to detect higher grade transformation in MZL is presently unknown, we suggest obtaining a tissue biopsy from highest SUV areas; especially, when significant discrepancies are observed between lesions. 37 We also suggest that all the patients will have multiparameter 4. SMZL that do not meet radiographically measurable disease criteria described herein are eligible for participation if lymphoma bone marrow infiltration is histologically confirmed and leads to clinically significant cytopenias (hemoglobin <10 g/dl, platelets <100 000/mm 3 , and/or neutrophils <1500/mm 3 ). Splenomegaly >13 cm should be considered measurable disease. ...
... The use of bispecific antibodies seems promising for R/R aggressive BCL patients, even after CAR T-cells failure 32 . Similar results have been reported in a US series, 26 suggesting that bispecific antibodies are a valid option. In our study, only a small sample of the censored patients (11patients) received this therapeutic strategy, and longer follow-up is needed for these patients, limiting any conclusions that can be drawn. ...
... Исходные характеристики этих пациентов имели благоприятный профиль: нормальный уровень лактатдегидрогеназы -ЛДГ (89%), низкий и средний риск по FLIPI (48 и 35%), отсутствие B-симптомов (97%) и низкую опухолевую нагрузку (72%). При медиане наблюдения 8 (5,(9)(10)(11)(12) лет только 64% этих пациентов в итоге начали противоопухолевую терапию (рис. 2) [2]. ...
... Recently, several studies have found that the PI3K/ AKT/mTOR signaling pathway is aberrantly activated in systemic DLBCL, participating in the occurrence and development of DLBCL [20][21][22][23][24]. The antitumor effect of the relevant inhibitor was also verified in cell and animal models [25][26][27]. In addition, the PI3K/AKT/mTOR signaling pathway could be activated by BCR activation [28,29], indicating there might be crosstalk between these two pathways. ...
... Nevertheless, the clinical data for ibrutinib monotherapy suggested its preferential efficacy toward non-GCB DLBCL and there is still unmet need in DLBCL. Mutations in MYD88, PLCγ2, CARD11, and TNFAIP3 contribute to acquire resistance to ibrutinib (Wilson et al. 2015;George et al. 2020). U2932 cell line is probably attributed to the TNFAIP3 mutation that confers resistance to BTK-targeting agents (George et al. 2020;Paul et al. 2017). ...
... For the most part, MSC secreted factors, especially IL-6, shelter CML cells from imatinib-induced apoptosis basically through NFκB-mediated signaling [74]. Chemoresistance in the diffuse large B-cell lymphoma (DLBCL) can be acquired by MSC secretion of IL-6 and upregulation of IL-17A [75]. ...